Device Trial Radar · NCT01913977
Clinical Study to Determine the Optimal Operation Parameters During CO2 Removal With the Abylcap® System
Last checked: Nov 19, 2026Latest source record: Dec 29, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
Feb 20, 2014
Primary completion
Jun 13, 2014
Study completion Sep 12, 2014
Sponsor
- Lead sponsor
- University Hospital, GhentAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 1, 2013
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This prospective study includes 5 patients with ARDS (Acute Respiratory Distress Syndrome) treated by mechanical ventilation. In case of respiratory acidosis, extracorporeal CO2 (carbon dioxide)removal might be necessary. We hereby work with the Abylcap system with the oxygenator Lilliput2 as CO2 remover (Bellco, Italy). The patients (M/V) are older than 18, not pregnant, have a BMI\<30, and no contraindication for anticoagulation therapy. Under standard conditions patients are treated with a blood flow of QB=300mL/min and a gas flow (100% 02) of QG=7L/min. Blood sampling is performed from the arterial bloodline in the patients at 0, 1h, 3h, 24h, 48h, 72h, 96h, and 120h. A parameter study is also performed to optimise CO2 removal. Herewith, blood samples (1mL) are taken from the inlet and outlet line of the Lilliput2 at the previously mentioned time points and for different flow setting: Blood flow (QB) 200-300-400mL/min and gas flow (QG) 1.5, 3, 6, 7, 8L/min Blood samples are analysed for the different blood gases from which the extraction in the CO2 remover can be calculated for each setting of QB (blood flow) and QG (gas flow).
Conditions
- ARDS (Acute Respiratory Distress Syndrome)
- Respiratory Acidosis
Interventions
Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/minDevice
Abylcap settings
Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/minDevice
Abylcap settings
Primary outcomes
What the sponsor says the trial is designed to measure.
- calculation of CO2 extraction in blood samples during mechanical ventilationTime frame: during mechanical ventilation with CO2 removal (max up to 120h)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ghent University Hospital
Ghent, Oost-Vlaanderen, Belgium
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.